Research ArticleErratum

Erratum to Assays for predicting and monitoring responses to lung cancer immunotherapy

Cristina Teixidó, Niki Karachaliou, Maria González-Cao, Daniela Morales-Espinosa and Rafael Rosell
Cancer Biology & Medicine September 2015, 12 (3) 259; DOI: https://doi.org/10.7497/j.issn.2095-3941.2015.0055

In the published article1, one error appeared on page 89.

Pembrolizumab has not yet received FDA approval for NSCLC patients. In October 2014 pembrolizumab received FDA breakthrough therapy designation for lung cancer treatment supported by data from a phase Ib trial in previously treated NSCLC patients2.

The authors apologize for the errors and for any confusion it may have caused.

Acknowledgements

We are thankful to Dr. Dickran Kazandjian from FDA/Office of Hematology and Oncology Products for pointing out this mistake.

  • Received July 28, 2015.
  • Accepted July 29, 2015.
https://creativecommons.org/licenses/by/4.0/

This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

References

  1. 1.↵
    2. Teixidó C,
    3. Karachaliou N,
    4. González-Cao M,
    5. Morales-Espinosa D,
    6. Rosell R.
    Assays for predicting and monitoring responses to lung cancer immunotherapy. Cancer Biol Med 2015;12:87–95.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    2. Garon EB,
    3. Rizvi NA,
    4. Hui R,
    5. Leighl N,
    6. Balmanoukian AS,
    7. Eder JP, et al.
    Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018–2028.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section